NRIX FY2025 SEC EDGAR DEF 14A #120 of 168 in industry

Nurix Therapeutics, Inc. CEO pay ratio

The CEO earned $6.3M in FY2025 against median worker pay of $274,252 · Chemicals & Pharmaceuticals.

Chemicals & Pharmaceuticals peers All rankings
State
DE
Filing date
2026-03-27
Industry
Chemicals & Pharmaceuticals
Industry rank
#120/168

Data updated August 2026

Subscribe to Nurix Therapeutics, Inc. CEO pay filing updates (RSS)

CEO-to-worker pay ratio
23:1
Below Average (Scale: 0–1000:1)
CEO pay
$6.3M
Median worker
$274,252

Answer first

Nurix Therapeutics, Inc.'s FY2025 CEO total of $6.3M ranks #823 of 1,423 complete filings; its 23:1 pay ratio ranks #1189. Dollar rank is not ratio rank.

According to the same FY2025 complete-filing cohort used on the rankings boards (CEO total, median worker, and ratio all present). Median worker pay is $274,252. Industry placement uses the FY2025 SIC-28 peer cohort (# 120 of 168, 29th percentile - below the industry median pay ratio). Figures come from Section 953(b) Dodd-Frank DEF 14A disclosures - not estimates. View all Chemicals & Pharmaceuticals companies.

Dollar rank
#823
$6.3M of 1,423 FY2025
Ratio rank
#1189
23:1 of 1,423
Industry pct
29th
below the industry median pay ratio

How Nurix Therapeutics, Inc. ranks nationally

Nurix Therapeutics, Inc. CEO pay vs. every FY2025 complete filing

Total CEO compensation, the full national distribution, this company marked

$6,307,796 42nd percentile higher than 42% of 1,423 companies

$0–$2,500,000: 304 companies (21%). Below this entry. $2,500,000–$5,000,000: 182 companies (13%). Below this entry. $5,000,000–$7,500,000: 208 companies (15%). This entry sits in this band. $7,500,000–$10,000,000: 192 companies (13%). Above this entry. $10,000,000–$12,500,000: 139 companies (10%). Above this entry. $12,500,000–$15,000,000: 91 companies (6%). Above this entry. $15,000,000–$17,500,000: 88 companies (6%). Above this entry. $17,500,000–$20,000,000: 54 companies (4%). Above this entry. $20,000,000–$22,500,000: 24 companies (2%). Above this entry. $22,500,000–$25,000,000: 34 companies (2%). Above this entry. $25,000,000–$27,500,000: 24 companies (2%). Above this entry. $27,500,000–$30,000,000: 16 companies (1%). Above this entry. $30,000,000–$32,500,000: 10 companies (1%). Above this entry. $32,500,000–$35,000,000: 7 companies (0%). Above this entry. $35,000,000–$37,500,000: 9 companies (1%). Above this entry. $37,500,000–$40,000,000: 6 companies (0%). Above this entry. $40,000,000–$42,500,000: 1 companies (0%). Above this entry. $42,500,000–$45,000,000: 1 companies (0%). Above this entry. $45,000,000–$47,500,000: 6 companies (0%). Above this entry. $47,500,000–$50,000,000: 27 companies (2%). Above this entry. This company $0 $50M+ every complete-filing company, bucketed by value

Each bar is a $2500K-wide band; taller bars hold more companies. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source SEC DEF 14A Section 953(b) disclosures, PlainCEOPay extract · FY2025

Nurix Therapeutics, Inc. vs. Chemicals & Pharmaceuticals peers

CEO total pay ($6.3M) against pay ratio (23:1) for Nurix Therapeutics, Inc. (marked) and its 5 closest same-industry peers, against the Chemicals & Pharmaceuticals industry median on both axes.

Pay + gap both highContained pay, wide gapHigh pay, contained gapBelow peer norms on both1865727.84015392.96165058.08314723.110464388.222.1:127.3:132.5:137.7:143.0:1CEO total payPay ratio (CEO : median worker)Nurix Therapeutics, Inc., CEO total pay: 6307796 · Pay ratio (CEO : median worker): 23:1Nurix Therapeutics, Inc.Kronos Worldwide Inc, CEO total pay: 2256576 · Pay ratio (CEO : median worker): 23:1Kronos Worldwide IncTravere Therapeutics, Inc., CEO total pay: 8457151 · Pay ratio (CEO : median worker): 23:1Travere Therapeutics, Inc.Schrodinger, Inc., CEO total pay: 4124521 · Pay ratio (CEO : median worker): 23:1Schrodinger, Inc.Axsome Therapeutics, Inc., CEO total pay: 10073540 · Pay ratio (CEO : median worker): 23:1Axsome Therapeutics, Inc.Praxis Precision Medicines, Inc., CEO total pay: 8708648 · Pay ratio (CEO : median worker): 23:1Praxis Precision Medicines, Inc.
Nurix Therapeutics, Inc. vs. Chemicals & Pharmaceuticals peers, plotted against the industry's $7.9M median CEO total and 42:1 median pay ratio.

Ratio bands among Chemicals & Pharmaceuticals peers

Exclusive CEO-to-median-worker bands across 153 complete latest-FY filings in SIC 28. Segments sum to the peer set, not this company's compensation pillar.

CEO Compensation Breakdown, FY2025

A component-level pay breakdown is not reported in Nurix Therapeutics, Inc.'s structured SEC pay-ratio disclosure. See our methodology →

Industry Comparison - Chemicals & Pharmaceuticals

This Company's Ratio
23:1
Industry Median Ratio
42:1
Industry Median CEO Pay
$7.9M
This CEO's Pay
$6.3M
Companies in Industry
168
vs. Industry Median
Below
#120 of 168 by pay ratio in this industry View all companies in Chemicals & Pharmaceuticals →

Nurix Therapeutics, Inc.: near-parity Item 402(u) ratio

Nurix Therapeutics, Inc.'s FY2025 ratio 23:1 ranks #120 of 168 Chemicals & Pharmaceuticals filers (29th percentile). the CEO earned 23× the median employee ($274,252) in FY2025.

At $274,252 median worker pay, the FLOOR stamp is near pay-parity territory under HEAVY CEO total.

CEO Total Pay

$6.3M

FY2025 Summary Compensation, below median

Pay Ratio

23:1

Below typical

Nurix Therapeutics, Inc. in the lower Chemicals & Pharmaceuticals third

Nurix Therapeutics, Inc.'s FY2025 ratio 23:1 ranks #120 of 168 Chemicals & Pharmaceuticals filers (29th percentile). The structured pay-ratio disclosure reports the total without line-item components. Chemicals & Pharmaceuticals (SIC 28) median ratio is 42:1 across 168 FY2025 filers; Nurix Therapeutics, Inc.'s $6.3M CEO total is at or below the $7.9M industry median CEO pay.

Dollar rank #823 and ratio rank #1189 split - treat 23:1 as a disclosure, not a fairness score. Open Chemicals & Pharmaceuticals peers.

Key Data, FY2025

Total Compensation
$6.3M
Median Employee Pay
$274,252
Pay Ratio
23:1
Filing Date
2026-03-27

Company Info

Ticker
NRIX
CIK
1549595
Industry
Chemicals & Pharmaceuticals
SIC Code
2834
State
DE
View SEC filings →
SEC EDGAR DEF 14A for CIK 1549595, FY2025. Informational only, not investment advice. Verify on EDGAR.

Read our methodology - how this data is sourced, computed, and verified. Nurix Therapeutics, Inc.'s FY2025 ratio 23:1 ranks #120 of 168 Chemicals & Pharmaceuticals filers (29th percentile).

Read with Nurix Therapeutics, Inc.

ABS(ceo_total_comp) peers first, then a SIC pole and a stamp-branched guide - not a fixed Related strip. This page stamps FLOOR · HEAVY · ELITE-MED.

Saia Inc · HEAVY

ABS(ceo_total_comp) peer at $6.3M (Δ $6K heavier vs Nurix Therapeutics, Inc.); MID · PAR-MED vs this page's FLOOR · HEAVY · ELITE-MED.
Funko, Inc. · HEAVY

ABS(ceo_total_comp) peer at $6.3M (Δ $12K lighter vs Nurix Therapeutics, Inc.); MID · PAR-MED vs this page's FLOOR · HEAVY · ELITE-MED.
First Hawaiian, Inc. · HEAVY

ABS(ceo_total_comp) peer at $6.3M (Δ $19K lighter vs Nurix Therapeutics, Inc.); MID · HIGH-MED vs this page's FLOOR · HEAVY · ELITE-MED.
10x Genomics, Inc. · HEAVY

ABS(ceo_total_comp) peer at $6.3M (Δ $21K heavier vs Nurix Therapeutics, Inc.); MODEST · ELITE-MED vs this page's FLOOR · HEAVY · ELITE-MED.
Kronos Worldwide Inc (SIC 28 pole)

Kronos Worldwide Inc stamps FLOOR · MID$ nearest in-SIC by ABS(pay_ratio) to Nurix Therapeutics, Inc.'s FLOOR filing.
National dual ranks · #823/#1189

Nurix Therapeutics, Inc.'s FY2025 package sits #823 by CEO dollars and #1189 by ratio under HEAVY · FLOOR.
Ratio primer · FLOOR

Nurix Therapeutics, Inc.'s FLOOR stamp sits in the lower Item 402(u) band - start with how the ratio is disclosed before comparing peers.
Data sourced from SEC EDGAR DEF 14A for Nurix Therapeutics, Inc. (CIK 1549595), FY2025. See our methodology. Aggregated by PlainCEOPay as of August 2026.

Data currency: Executive compensation from SEC EDGAR DEF 14A proxy statements through fiscal year 2025, compiled and last refreshed August 2026. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.